THU0252 Decreased Expression of Immunoregulatory Protein Programmed Death Ligand-1 (PD-L1) in Systemic Lupus Erythematosus (SLE) Placenta

BackgroundThe increased rates of preeclampsia, pre-term birth, and intra-uterine growth restriction in SLE pregnancy are only partially explained by the vascular effects of anti-phospholipid antibodies. SLE patients themselves are on average born preterm, suggesting a heritable defect in maternal-fe...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Annals of the rheumatic diseases 2016-06, Vol.75 (Suppl 2), p.279
Hauptverfasser: Stevens, A.M., Yuasa, M., Deutsch, G.
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue Suppl 2
container_start_page 279
container_title Annals of the rheumatic diseases
container_volume 75
creator Stevens, A.M.
Yuasa, M.
Deutsch, G.
description BackgroundThe increased rates of preeclampsia, pre-term birth, and intra-uterine growth restriction in SLE pregnancy are only partially explained by the vascular effects of anti-phospholipid antibodies. SLE patients themselves are on average born preterm, suggesting a heritable defect in maternal-fetal tolerance. PD-L1 is one candidate gene, in that it has been implicated in the both autoimmunity and maternal-fetal tolerance: PD-L1 is expressed on healthy antigen presenting cells to downregulate inflammatory responses, and also on placental trophoblasts at the maternal-fetal interface, where it inhibits alloreactive T cells. Peripheral blood antigen presenting cells from SLE patients are deficient in PD-L1 expression compared to remission or healthy controls. Little is known about placental costimulatory molecules in women with autoimmune diseases.ObjectivesThis study tested the hypothesis that placental PD-L1 expression is abnormally regulated in SLE pregnancy.MethodsExpression of PD-L1 was quantified by immunohistochemistry in placentas from 6 SLE patients, 7 rheumatoid arthritis patients (RA) and 9 healthy control women obtained from the Global Alliance for the Prevention of Prematurity and Stillbirth Repository. PD-L1 mRNA expression was assayed by RT-PCR and normalized to GAPDH expression. PD-L1 on peripheral CD14+/CD11c+ monocytes was assayed by flow cytometry. Significant differences between groups were tested by T-test.ResultsBy immunostaining, PD-L1 expression in SLE placentas was low compared to control groups. PD-L1 mRNA expression correlated with protein expression, although the differences were not significant. A limited analysis of CD45 and CD43 co-expression suggested that a subset of maternal T lymphocytes expressed PDL-1 but that fetal cells did not. The mean gestational age was lower in SLE (27 weeks, range 18–39) compared to RA (38, range 29–40) and controls (34, range 19–40), but there was not a strong correlation between gestational age and PD-L1 expression (R2 0.18). Three SLE patients exhibited placental insufficiency, with relatively low PD-L1 expression (18 compared to 24 in healthy SLE). On peripheral blood monocytes, PD-L1 expression was low in juvenile SLE patients compared to healthy controls (55% of SLE monocytes v. 93% of healthy monocytes, p=0.001). Although in the normal range, mothers of SLE patients also had relatively low PD-L1 expression compared to control mothers (87% v. 94%, p=0.04).Table 1.Relative mean PD-L1 expres
doi_str_mv 10.1136/annrheumdis-2016-eular.5911
format Article
fullrecord <record><control><sourceid>proquest_bmj_p</sourceid><recordid>TN_cdi_proquest_journals_1901882052</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>4322515987</sourcerecordid><originalsourceid>FETCH-LOGICAL-b752-fcfc5e516220159d7fbb8ef7eefbbd983cef7e1100a660cc893c0b46fcd3041c3</originalsourceid><addsrcrecordid>eNpNkLFOwzAQhi0EEqXwDpa6tEOKL2ncZERtoZUiUallthzn0qaqk2AnEtlYmHhLngQHGJju_tN__-k-QkbApgABv5dlaY7Y6qywns-Ae9iepZmGMcAFGcCMR27M2SUZMMYCbxbz-TW5sfbkJIsgGpDP_fqF-aH_9f6xRGVQWszo6q02aG1RlbTK6UbrtqwMHlx2U5mObk3VYFH29WCk1m5jibI50qQ4yDLzgI63Sy-BCXWmXWcb1IWiSVu3lq5M1xxRuyDr1HiXrCZ0e5YKy0bekqtcni3e_dUh2T-u9ou1lzw_bRYPiZfOQ9_LVa5CDIH77uMwzuZ5mkaYzxFdk8VRoHoBwJjknCkVxYFi6YznKgvYDFQwJKPf2NpUry3aRpyq1pTuooCYQRT5LPSdi_-6Un0StSm0NJ0AJnru4h930XMXP9xFzz34BhKlfbo</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1901882052</pqid></control><display><type>article</type><title>THU0252 Decreased Expression of Immunoregulatory Protein Programmed Death Ligand-1 (PD-L1) in Systemic Lupus Erythematosus (SLE) Placenta</title><source>BMJ Journals - NESLi2</source><creator>Stevens, A.M. ; Yuasa, M. ; Deutsch, G.</creator><creatorcontrib>Stevens, A.M. ; Yuasa, M. ; Deutsch, G.</creatorcontrib><description>BackgroundThe increased rates of preeclampsia, pre-term birth, and intra-uterine growth restriction in SLE pregnancy are only partially explained by the vascular effects of anti-phospholipid antibodies. SLE patients themselves are on average born preterm, suggesting a heritable defect in maternal-fetal tolerance. PD-L1 is one candidate gene, in that it has been implicated in the both autoimmunity and maternal-fetal tolerance: PD-L1 is expressed on healthy antigen presenting cells to downregulate inflammatory responses, and also on placental trophoblasts at the maternal-fetal interface, where it inhibits alloreactive T cells. Peripheral blood antigen presenting cells from SLE patients are deficient in PD-L1 expression compared to remission or healthy controls. Little is known about placental costimulatory molecules in women with autoimmune diseases.ObjectivesThis study tested the hypothesis that placental PD-L1 expression is abnormally regulated in SLE pregnancy.MethodsExpression of PD-L1 was quantified by immunohistochemistry in placentas from 6 SLE patients, 7 rheumatoid arthritis patients (RA) and 9 healthy control women obtained from the Global Alliance for the Prevention of Prematurity and Stillbirth Repository. PD-L1 mRNA expression was assayed by RT-PCR and normalized to GAPDH expression. PD-L1 on peripheral CD14+/CD11c+ monocytes was assayed by flow cytometry. Significant differences between groups were tested by T-test.ResultsBy immunostaining, PD-L1 expression in SLE placentas was low compared to control groups. PD-L1 mRNA expression correlated with protein expression, although the differences were not significant. A limited analysis of CD45 and CD43 co-expression suggested that a subset of maternal T lymphocytes expressed PDL-1 but that fetal cells did not. The mean gestational age was lower in SLE (27 weeks, range 18–39) compared to RA (38, range 29–40) and controls (34, range 19–40), but there was not a strong correlation between gestational age and PD-L1 expression (R2 0.18). Three SLE patients exhibited placental insufficiency, with relatively low PD-L1 expression (18 compared to 24 in healthy SLE). On peripheral blood monocytes, PD-L1 expression was low in juvenile SLE patients compared to healthy controls (55% of SLE monocytes v. 93% of healthy monocytes, p=0.001). Although in the normal range, mothers of SLE patients also had relatively low PD-L1 expression compared to control mothers (87% v. 94%, p=0.04).Table 1.Relative mean PD-L1 expression in placentaControlsSLEP*RAP**ProteinMean39210.012370.63Fetal391636Maternal412334mRNA109720.213000.08*SLE versus controls; **RA versus controls.ConclusionsPlacental PD-L1 expression is dysregulated in women with SLE. Inadequate expression of PDL-1 in the placentas of patients with SLE could result in loss of maternal-fetal tolerance, contributing to the high rate of pregnancy complications in SLE.Disclosure of InterestNone declared</description><identifier>ISSN: 0003-4967</identifier><identifier>EISSN: 1468-2060</identifier><identifier>DOI: 10.1136/annrheumdis-2016-eular.5911</identifier><identifier>CODEN: ARDIAO</identifier><language>eng</language><publisher>London: BMJ Publishing Group LTD</publisher><ispartof>Annals of the rheumatic diseases, 2016-06, Vol.75 (Suppl 2), p.279</ispartof><rights>2016, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions</rights><rights>Copyright: 2016 (c) 2016, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttp://ard.bmj.com/content/75/Suppl_2/279.1.full.pdf$$EPDF$$P50$$Gbmj$$H</linktopdf><linktohtml>$$Uhttp://ard.bmj.com/content/75/Suppl_2/279.1.full$$EHTML$$P50$$Gbmj$$H</linktohtml><link.rule.ids>114,115,314,780,784,23571,27924,27925,77600,77631</link.rule.ids></links><search><creatorcontrib>Stevens, A.M.</creatorcontrib><creatorcontrib>Yuasa, M.</creatorcontrib><creatorcontrib>Deutsch, G.</creatorcontrib><title>THU0252 Decreased Expression of Immunoregulatory Protein Programmed Death Ligand-1 (PD-L1) in Systemic Lupus Erythematosus (SLE) Placenta</title><title>Annals of the rheumatic diseases</title><description>BackgroundThe increased rates of preeclampsia, pre-term birth, and intra-uterine growth restriction in SLE pregnancy are only partially explained by the vascular effects of anti-phospholipid antibodies. SLE patients themselves are on average born preterm, suggesting a heritable defect in maternal-fetal tolerance. PD-L1 is one candidate gene, in that it has been implicated in the both autoimmunity and maternal-fetal tolerance: PD-L1 is expressed on healthy antigen presenting cells to downregulate inflammatory responses, and also on placental trophoblasts at the maternal-fetal interface, where it inhibits alloreactive T cells. Peripheral blood antigen presenting cells from SLE patients are deficient in PD-L1 expression compared to remission or healthy controls. Little is known about placental costimulatory molecules in women with autoimmune diseases.ObjectivesThis study tested the hypothesis that placental PD-L1 expression is abnormally regulated in SLE pregnancy.MethodsExpression of PD-L1 was quantified by immunohistochemistry in placentas from 6 SLE patients, 7 rheumatoid arthritis patients (RA) and 9 healthy control women obtained from the Global Alliance for the Prevention of Prematurity and Stillbirth Repository. PD-L1 mRNA expression was assayed by RT-PCR and normalized to GAPDH expression. PD-L1 on peripheral CD14+/CD11c+ monocytes was assayed by flow cytometry. Significant differences between groups were tested by T-test.ResultsBy immunostaining, PD-L1 expression in SLE placentas was low compared to control groups. PD-L1 mRNA expression correlated with protein expression, although the differences were not significant. A limited analysis of CD45 and CD43 co-expression suggested that a subset of maternal T lymphocytes expressed PDL-1 but that fetal cells did not. The mean gestational age was lower in SLE (27 weeks, range 18–39) compared to RA (38, range 29–40) and controls (34, range 19–40), but there was not a strong correlation between gestational age and PD-L1 expression (R2 0.18). Three SLE patients exhibited placental insufficiency, with relatively low PD-L1 expression (18 compared to 24 in healthy SLE). On peripheral blood monocytes, PD-L1 expression was low in juvenile SLE patients compared to healthy controls (55% of SLE monocytes v. 93% of healthy monocytes, p=0.001). Although in the normal range, mothers of SLE patients also had relatively low PD-L1 expression compared to control mothers (87% v. 94%, p=0.04).Table 1.Relative mean PD-L1 expression in placentaControlsSLEP*RAP**ProteinMean39210.012370.63Fetal391636Maternal412334mRNA109720.213000.08*SLE versus controls; **RA versus controls.ConclusionsPlacental PD-L1 expression is dysregulated in women with SLE. Inadequate expression of PDL-1 in the placentas of patients with SLE could result in loss of maternal-fetal tolerance, contributing to the high rate of pregnancy complications in SLE.Disclosure of InterestNone declared</description><issn>0003-4967</issn><issn>1468-2060</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNpNkLFOwzAQhi0EEqXwDpa6tEOKL2ncZERtoZUiUallthzn0qaqk2AnEtlYmHhLngQHGJju_tN__-k-QkbApgABv5dlaY7Y6qywns-Ae9iepZmGMcAFGcCMR27M2SUZMMYCbxbz-TW5sfbkJIsgGpDP_fqF-aH_9f6xRGVQWszo6q02aG1RlbTK6UbrtqwMHlx2U5mObk3VYFH29WCk1m5jibI50qQ4yDLzgI63Sy-BCXWmXWcb1IWiSVu3lq5M1xxRuyDr1HiXrCZ0e5YKy0bekqtcni3e_dUh2T-u9ou1lzw_bRYPiZfOQ9_LVa5CDIH77uMwzuZ5mkaYzxFdk8VRoHoBwJjknCkVxYFi6YznKgvYDFQwJKPf2NpUry3aRpyq1pTuooCYQRT5LPSdi_-6Un0StSm0NJ0AJnru4h930XMXP9xFzz34BhKlfbo</recordid><startdate>201606</startdate><enddate>201606</enddate><creator>Stevens, A.M.</creator><creator>Yuasa, M.</creator><creator>Deutsch, G.</creator><general>BMJ Publishing Group LTD</general><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88I</scope><scope>8AF</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>BTHHO</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9-</scope><scope>K9.</scope><scope>LK8</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>M2P</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope></search><sort><creationdate>201606</creationdate><title>THU0252 Decreased Expression of Immunoregulatory Protein Programmed Death Ligand-1 (PD-L1) in Systemic Lupus Erythematosus (SLE) Placenta</title><author>Stevens, A.M. ; Yuasa, M. ; Deutsch, G.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b752-fcfc5e516220159d7fbb8ef7eefbbd983cef7e1100a660cc893c0b46fcd3041c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Stevens, A.M.</creatorcontrib><creatorcontrib>Yuasa, M.</creatorcontrib><creatorcontrib>Deutsch, G.</creatorcontrib><collection>ProQuest Central (Corporate)</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>STEM Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>BMJ Journals</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><jtitle>Annals of the rheumatic diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Stevens, A.M.</au><au>Yuasa, M.</au><au>Deutsch, G.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>THU0252 Decreased Expression of Immunoregulatory Protein Programmed Death Ligand-1 (PD-L1) in Systemic Lupus Erythematosus (SLE) Placenta</atitle><jtitle>Annals of the rheumatic diseases</jtitle><date>2016-06</date><risdate>2016</risdate><volume>75</volume><issue>Suppl 2</issue><spage>279</spage><pages>279-</pages><issn>0003-4967</issn><eissn>1468-2060</eissn><coden>ARDIAO</coden><abstract>BackgroundThe increased rates of preeclampsia, pre-term birth, and intra-uterine growth restriction in SLE pregnancy are only partially explained by the vascular effects of anti-phospholipid antibodies. SLE patients themselves are on average born preterm, suggesting a heritable defect in maternal-fetal tolerance. PD-L1 is one candidate gene, in that it has been implicated in the both autoimmunity and maternal-fetal tolerance: PD-L1 is expressed on healthy antigen presenting cells to downregulate inflammatory responses, and also on placental trophoblasts at the maternal-fetal interface, where it inhibits alloreactive T cells. Peripheral blood antigen presenting cells from SLE patients are deficient in PD-L1 expression compared to remission or healthy controls. Little is known about placental costimulatory molecules in women with autoimmune diseases.ObjectivesThis study tested the hypothesis that placental PD-L1 expression is abnormally regulated in SLE pregnancy.MethodsExpression of PD-L1 was quantified by immunohistochemistry in placentas from 6 SLE patients, 7 rheumatoid arthritis patients (RA) and 9 healthy control women obtained from the Global Alliance for the Prevention of Prematurity and Stillbirth Repository. PD-L1 mRNA expression was assayed by RT-PCR and normalized to GAPDH expression. PD-L1 on peripheral CD14+/CD11c+ monocytes was assayed by flow cytometry. Significant differences between groups were tested by T-test.ResultsBy immunostaining, PD-L1 expression in SLE placentas was low compared to control groups. PD-L1 mRNA expression correlated with protein expression, although the differences were not significant. A limited analysis of CD45 and CD43 co-expression suggested that a subset of maternal T lymphocytes expressed PDL-1 but that fetal cells did not. The mean gestational age was lower in SLE (27 weeks, range 18–39) compared to RA (38, range 29–40) and controls (34, range 19–40), but there was not a strong correlation between gestational age and PD-L1 expression (R2 0.18). Three SLE patients exhibited placental insufficiency, with relatively low PD-L1 expression (18 compared to 24 in healthy SLE). On peripheral blood monocytes, PD-L1 expression was low in juvenile SLE patients compared to healthy controls (55% of SLE monocytes v. 93% of healthy monocytes, p=0.001). Although in the normal range, mothers of SLE patients also had relatively low PD-L1 expression compared to control mothers (87% v. 94%, p=0.04).Table 1.Relative mean PD-L1 expression in placentaControlsSLEP*RAP**ProteinMean39210.012370.63Fetal391636Maternal412334mRNA109720.213000.08*SLE versus controls; **RA versus controls.ConclusionsPlacental PD-L1 expression is dysregulated in women with SLE. Inadequate expression of PDL-1 in the placentas of patients with SLE could result in loss of maternal-fetal tolerance, contributing to the high rate of pregnancy complications in SLE.Disclosure of InterestNone declared</abstract><cop>London</cop><pub>BMJ Publishing Group LTD</pub><doi>10.1136/annrheumdis-2016-eular.5911</doi></addata></record>
fulltext fulltext
identifier ISSN: 0003-4967
ispartof Annals of the rheumatic diseases, 2016-06, Vol.75 (Suppl 2), p.279
issn 0003-4967
1468-2060
language eng
recordid cdi_proquest_journals_1901882052
source BMJ Journals - NESLi2
title THU0252 Decreased Expression of Immunoregulatory Protein Programmed Death Ligand-1 (PD-L1) in Systemic Lupus Erythematosus (SLE) Placenta
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-03T06%3A42%3A23IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_bmj_p&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=THU0252%E2%80%85Decreased%20Expression%20of%20Immunoregulatory%20Protein%20Programmed%20Death%20Ligand-1%20(PD-L1)%20in%20Systemic%20Lupus%20Erythematosus%20(SLE)%20Placenta&rft.jtitle=Annals%20of%20the%20rheumatic%20diseases&rft.au=Stevens,%20A.M.&rft.date=2016-06&rft.volume=75&rft.issue=Suppl%202&rft.spage=279&rft.pages=279-&rft.issn=0003-4967&rft.eissn=1468-2060&rft.coden=ARDIAO&rft_id=info:doi/10.1136/annrheumdis-2016-eular.5911&rft_dat=%3Cproquest_bmj_p%3E4322515987%3C/proquest_bmj_p%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1901882052&rft_id=info:pmid/&rfr_iscdi=true